Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
23.8M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
714K
-
Shares change
-
+204K
-
Total reported value, excl. options
-
$1.21M
-
Value change
-
+$328K
-
Put/Call ratio
-
0.02
-
Number of buys
-
7
-
Number of sells
-
-6
-
Price
-
$1.69
Significant Holders of NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value (NRXP) as of Q3 2024
24 filings reported holding NRXP - NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q3 2024.
NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value (NRXP) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 714K shares
of 23.8M outstanding shares and own 3% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (240K shares), Anson Funds Management LP (143K shares), AdvisorShares Investments LLC (130K shares), GEODE CAPITAL MANAGEMENT, LLC (77.3K shares), SABBY MANAGEMENT, LLC (35K shares), BlackRock, Inc. (29.1K shares), STATE STREET CORP (16.7K shares), One Wealth Management Investment & Advisory Services, LLC (15K shares), TOWNSQUARE CAPITAL LLC (15K shares), and MORGAN STANLEY (4.4K shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.